Skip to main content
Erschienen in: Neurological Sciences 6/2019

01.06.2019 | Letter to the Editor

Malignant syndrome triggered by influenza A virus infection in a patient with Parkinson’s disease with improvement after intravenous peramivir treatment

verfasst von: Kosuke Matsuzono, Masamichi Baba, Goro Imai, Hiroaki Imai, Shigeru Fujimoto

Erschienen in: Neurological Sciences | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Excerpt

Malignant syndrome, also called parkinsonism-hyperpyrexia syndrome, is a rare medical emergency in patients with Parkinson’s disease (PD). The precipitating events that trigger malignant syndrome in patients with PD are anti-parkinsonian drug withdrawal and stress-related factors [1, 2]. Infection is a major cause of malignant syndrome, and fever is considered the trigger [1]. However, the relationship among malignant syndrome, influenza virus infection, and treatment for influenza virus remains unclear. We herein report a case involving a man with PD who developed malignant syndrome secondary to influenza A virus infection but improved after intravenous peramivir treatment without dantrolene. …
Literatur
1.
Zurück zum Zitat Hashimoto T, Tokuda T, Hanyu N, Tabata K, Yanagisawa N (2003) Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord 9(Suppl 1):S25–S30CrossRefPubMed Hashimoto T, Tokuda T, Hanyu N, Tabata K, Yanagisawa N (2003) Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord 9(Suppl 1):S25–S30CrossRefPubMed
2.
Zurück zum Zitat Ogawa E, Sakakibara R, Kishi M, Tateno F (2012) Constipation triggered the malignant syndrome in Parkinson's disease. Neurol Sci 33:347–350CrossRefPubMed Ogawa E, Sakakibara R, Kishi M, Tateno F (2012) Constipation triggered the malignant syndrome in Parkinson's disease. Neurol Sci 33:347–350CrossRefPubMed
4.
Zurück zum Zitat Takubo H, Harada T, Hashimoto T et al (2003) A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 9(Suppl 1):S31–S41CrossRefPubMed Takubo H, Harada T, Hashimoto T et al (2003) A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 9(Suppl 1):S31–S41CrossRefPubMed
5.
Zurück zum Zitat Lattanzi L, Mungai F, Romano A, Bonuccelli U, Cassano GB, Fagiolini A (2006) Subcutaneous apomorphine for neuroleptic malignant syndrome. Am J Psychiatry 163:1450–1451CrossRefPubMed Lattanzi L, Mungai F, Romano A, Bonuccelli U, Cassano GB, Fagiolini A (2006) Subcutaneous apomorphine for neuroleptic malignant syndrome. Am J Psychiatry 163:1450–1451CrossRefPubMed
7.
Zurück zum Zitat Shetty AK, Peek LA (2012) Peramivir for the treatment of influenza. Expert Rev Anti-Infect Ther 10:123–143CrossRefPubMed Shetty AK, Peek LA (2012) Peramivir for the treatment of influenza. Expert Rev Anti-Infect Ther 10:123–143CrossRefPubMed
8.
Zurück zum Zitat Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T (2012) Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369–377CrossRefPubMedPubMedCentral Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T (2012) Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369–377CrossRefPubMedPubMedCentral
Metadaten
Titel
Malignant syndrome triggered by influenza A virus infection in a patient with Parkinson’s disease with improvement after intravenous peramivir treatment
verfasst von
Kosuke Matsuzono
Masamichi Baba
Goro Imai
Hiroaki Imai
Shigeru Fujimoto
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 6/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3696-4

Weitere Artikel der Ausgabe 6/2019

Neurological Sciences 6/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.